CDC Panel on J&J (JNJ) Shot Concludes Without Vote, More Data Needed - Bloomberg
- S&P 500, Dow end at record highs as weak jobs data eases rate worries
- U.S. Added Only 266,000 Jobs in April, Well Below Estimates
- Roku (ROKU) Surges After Crushing Profit Estimates to Prompt an Upgrade to 'Buy' at Loop Capital
- Dollar broadly weaker after U.S. jobs data disappoint
- Square (SQ) Tops Q1 EPS by 25c
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
CDC Panel on Johnson & Johnson (NYSE: JNJ) Shot Concludes Without Vote, More Data Needed - Bloomberg
- Decision Effectively Extends U.S. Pause on Vaccine
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- White House Says Biden Will Outline Plans To Make Covid-19 Vaccine More Accessible Across U.S. - Reuters
- T2 Biosystems (TTOO) Accelerates Product Development Initiatives as Part of BARDA Agreement
- ChemoCentryx (CCXI) Crashes 55% on Mixed AdComm Results, Gets Downgraded at Five Firms
Create E-mail Alert Related CategoriesFDA, Hot FDA News
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!